Valeriya Klats, MD
Pain Medicine · Bronx, NYNPI 1134506678
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,174 of the $70,611 with a category attached, or 85.2%. AbbVie accounts for 60.8% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $33,492, more than ten times the $57 reported in 2020. Among pain medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 339 payments — averaging $208.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Pfizer$26K
- Lundbeck LLC$386
- Biohaven Pharmaceutical Holding Company Ltd.$291
- Biohaven Pharmaceuticals, Inc.$259
- Lilly USA, LLC$237
- plus $692 from 13 others
What the payments were for
- Consulting fees$4,9257%
- Speaking & faculty fees$60,17485%
- Travel & lodging$4251%
- Food & beverage$5,0517%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 158 | $42,919 |
| Pfizer | 74 | $25,826 |
| Lundbeck LLC | 31 | $386 |
| Biohaven Pharmaceutical Holding Company Ltd. | 32 | $291 |
| Biohaven Pharmaceuticals, Inc. | 8 | $259 |
| Lilly USA, LLC | 8 | $237 |
| Novo Nordisk | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 4 | $90 |
| Impel Pharmaceuticals Inc. | 3 | $74 |
| Neurocrine Biosciences, Inc. | 3 | $71 |
| Amgen | 3 | $66 |
| Adamas Pharmaceuticals, Inc. | 3 | $63 |
| Amneal Pharmaceuticals LLC | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 2 | $44 |
| Upsher-smith Laboratories LLC | 2 | $33 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| MDD US Operations, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,611 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 44 | $52,018 |
| Emgality PenGalcanezumab-Gnlm | 41 | $36,348 |
| UbrelvyUbrogepant | 24 | $29,770 |
| BotoxOnabotulinumtoxina | 19 | $24,684 |
| Aimovig AutoinjectorErenumab-Aooe | 29 | $22,052 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $15,150 |
| QuliptaAtogepant | 11 | $11,588 |
| Candesartan Cilexetil | 22 | $984 |
| Gabapentin | 83 | $907 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $712 |
| Topiramate | 52 | $433 |
| Nortriptyline Hcl | 24 | $418 |
| RizatriptanRizatriptan Benzoate | 26 | $258 |
| Tizanidine Hcl | 27 | $230 |
| Cyclobenzaprine Hcl | 11 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $42,919 | $66,04254 claims |
| PfizerNurtec Odt | $25,826 | $52,01844 claims |
| Upsher-smith Laboratories LLCTopiramate | $33 | $43352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.
Other pain medicine in Bronx
- Fred CohenBronx$141K
- Naum ShaparinBronx$70K
- Gary SchwartzBrooklyn$756K
- Amitabh GulatiNew York$614K
- William CaldwellStony Brook$530K
- Brian DurkinPort Jefferson$455K
- David SpinnerNew York$391K
- Grace FordeNew Hyde Park$355K
- Romanth WaghmaraeHamburg$158K
- Samuel BrownSouthold$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.